GlaxoSmithKline (GSK) has agreed to acquire Rapt Therapeutics for $2.2 billion, the companies said today, in a deal intended to bolster the buyer’s pipeline with Rapt’s ozureprubart (RPT904), a ...
The company applies AI to optimize molecules across discovery and production with aims to contribute to the rebuilding of U.S.-based drug innovation and manufacturing.
Astellas Gene Therapies remains intent on treating X-linked Myotubular Myopathy (XLMTM) through a gene therapy—but instead of AAV-based resamirigene bilparvovec (AT132), Astellas is now partnering ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback